PIRO Score for Community-Acquired Pneumonia
Why Use
Consists of easily accessible variables known to impact CAP mortality. Unlike similar tools, PIRO is specifically tailored for severe CAP cases requiring ICU admission. Predicts 28-day mortality and ICU resource utilization. Identifies high-risk patients who may need closer monitoring and more aggressive management. Facilitates risk stratification for clinical research on novel or targeted therapies. Outperformed APACHE II and the 2007 ATS/IDSA CAP severity/management criteria in predicting mortality in the derivation study.
When to Use
Use within 24 hours of a community-acquired pneumonia (CAP) diagnosis in adults (≥18 years) to assess disease severity and predict mortality.
Formula
Pearls / Pitfalls
Developed using data from 529 patients with severe CAP admitted to ICUs across 33 hospitals in Spain. Variability in ICU admission criteria for CAP may lead to differences in mortality rates between institutions. Although designed for ICU patients, the score has been validated in general ward and emergency department settings; however, its predictive accuracy remains strongest for critically-ill patients. Does not incorporate biomarker data (e.g., procalcitonin), which may also aid in risk assessment.
Advice
No specific management guidelines are linked to PIRO score results. Higher scores correlate with increased mortality, prolonged ICU stay, and extended mechanical ventilation. Results may inform prognosis discussions and guide decisions on treatment setting (e.g., ICU, stepdown, medical ward), aggressive interventions, and adjunctive therapies (e.g., corticosteroids).
More Information
Interpretation: PIRO Score for CAP Risk Level 28-day Mortality 0-2 Low 3.6% 3 Mild 13.0% 4 High 43.0% 5-8 Very high 76.3%